Evidence map›Paper›PMID 38177923›Full record

ArticleEMBO reports2024

The immediate-early protein 1 of human herpesvirus 6B interacts with NBS1 and inhibits ATM signaling.

Vanessa Collin, Élise Biquand, Vincent Tremblay, Élise G Lavoie, Andréanne Blondeau, Annie Gravel, Maxime Galloy, Anahita Lashgari, Julien Dessapt, Jacques Côté and 2 more

Open access · diamondAbstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Vanessa Collin *Division of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada.ORCID http://orcid.org/0000-0002-6319-248X
Élise Biquand *Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0001-9387-2550
Vincent Tremblay *Oncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.
Élise G LavoieOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0002-5836-4785
Andréanne BlondeauOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0002-3989-0261
Annie GravelDivision of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada.ORCID http://orcid.org/0000-0001-5229-5750
Maxime GalloyOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0009-0009-8779-1098
Anahita LashgariOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0001-7525-6252
Julien DessaptOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0001-5748-3320
Jacques CôtéOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada.ORCID http://orcid.org/0000-0001-6751-555X
Louis FlamandDivision of Infectious Disease and Immunity, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1V 4G2, Canada. louis.flamand@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0001-5010-4586
Amélie Fradet-TurcotteOncology Division, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, G1R 2J6, Canada. amelie.fradet-turcotte@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0002-5431-8650
Centre hospitalier universitaire de Québec · CAUniversité de Tours · FR

Funding

FRQ | Fonds de recherche du Québec - Nature et technologies (FRQNT) MSc scholarshipFRQ | Fonds de Recherche du Québec - Santé (FRQS) PDF scholarshipFRQ | Fonds de Recherche du Québec - Santé (FRQS) PhD scholarshipGouvernement du Canada | Canadian Institutes of Health Research (IRSC) FDN-143314Gouvernement du Canada | Canadian Institutes of Health Research (IRSC) MOP_123214Gouvernement du Canada | Canadian Institutes of Health Research (IRSC) PJT_152948Gouvernement du Canada | Canadian Institutes of Health Research (IRSC) PJT_156118
6 · The paper itself

Abstract

Viral infection often trigger an ATM serine/threonine kinase (ATM)-dependent DNA damage response in host cells that suppresses viral replication. Viruses evolved different strategies to counteract this antiviral surveillance system. Here, we report that human herpesvirus 6B (HHV-6B) infection causes genomic instability by suppressing ATM signaling in host cells. Expression of immediate-early protein 1 (IE1) phenocopies this phenotype and blocks homology-directed double-strand break repair. Mechanistically, IE1 interacts with NBS1, and inhibits ATM signaling through two distinct domains. HHV-6B seems to efficiently inhibit ATM signaling as further depletion of either NBS1 or ATM do not significantly boost viral replication in infected cells. Interestingly, viral integration of HHV-6B into the host's telomeres is not strictly dependent on NBS1, challenging current models where integration occurs through homology-directed repair. Given that spontaneous IE1 expression has been detected in cells of subjects with inherited chromosomally-integrated form of HHV-6B (iciHHV-6B), a condition associated with several health conditions, our results raise the possibility of a link between genomic instability and the development of iciHHV-6-associated diseases.

Indexed as

Herpesvirus 6, HumanImmediate-Early ProteinsRoseolovirus InfectionsAtaxia Telangiectasia Mutated ProteinsGenomic InstabilityHumansVirus IntegrationAtaxia Telangiectasia Mutated ProteinsATM protein, humanImmediate-Early ProteinsDNA Double-Strand Break SignalingHuman Herpesvirus 6A/BImmediate-Early Protein IE1IntegrationTelomere

Identifiers

PMID38177923
PMCPMC10897193
OpenAlexW4390512886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.